Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

3 Stocks to Buy in the Booming Field of Gene Editing

January 11, 2024

Via InvestorPlace

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

January 08, 2024

Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024

January 08, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

January 05, 2024

Via Investor's Business Daily

Is Beam Therapeutics Stock a Buy Now?

November 18, 2023

It has plenty of money, but it'll be facing plenty of competition, too.

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

Wall Street is uber-bullish on these two Ark Invest holdings.

2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

Via MarketBeat

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

December 14, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Beam Therapeutics: Q3 Earnings Insights

November 08, 2023

Via Benzinga

Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday

December 08, 2023

Via Benzinga

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception

November 29, 2023

The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.

Via Benzinga

Topics ETFs

The 3 Best Gene Editing Stocks on the Frontier of Medicine

November 20, 2023

Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.

Via InvestorPlace

3 Monster Stocks in the Making

November 18, 2023

These stocks could grow much larger over the next few years.

You might not get a better chance to invest in these disruptive companies.

Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks

November 14, 2023

Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session

November 13, 2023

Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.

Via Benzinga

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

November 08, 2023

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

November 08, 2023

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

Via Investor's Business Daily

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now

November 05, 2023

These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors.

Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.

Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On

November 01, 2023

Via InvestorPlace

Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today

October 31, 2023

Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology.

Eli Lilly now owns the opt-in rights to three more of Verve's cardiovascular drugs.

Verve Stock Soars On $250 Million Eli Lilly Deal

October 31, 2023

Via Investor's Business Daily

Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday

October 31, 2023

U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

October 31, 2023

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for...

Via Benzinga

Topics Intellectual Property

After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?

October 31, 2023

Some of the strategic shifts proposed by management are for the better.

Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's

Why Beam Therapeutics Stock Is Getting Bought Today

October 31, 2023

Via Benzinga

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

October 31, 2023

Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026